Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Melanoma/Skin Cancer Health Center

Font Size

Zelboraf May Double Survival for Some Melanoma Patients

New Drug Extends Life, Lessens Pain for Many Patients With Common Form of Advanced Melanoma
WebMD Health News
Reviewed by Laura J. Martin, MD

Feb. 22, 2012 -- The newly approved drug Zelboraf appears to nearly double the length of time a person can expect to live with advanced melanoma skin cancer, a new study shows.

Melanoma kills about 9,000 Americans each year, and it often progresses quickly. Studies have found that the midpoint in survival time for patients on standard chemotherapy is just six to 10 months for patients with melanoma that has spread to other organs.

Last year, the FDA fast-tracked approval for Zelboraf, a pill that targets a specific mutation in the BRAF gene that’s present in about half of all melanomas.

At the time it was approved, studies showed the drug was shrinking tumors in most patients who took it, but researchers had not been following patients long enough to know how it might affect long-term survival.

The new study, which is published in the New England Journal of Medicine, followed a group of 132 patients taking Zelboraf for an average of 13 months.

Drug May Buy Patients More Time

More than half of the patients in the study saw their tumors shrink by at least 30%. In another 33% of patients, the drug slowed or stopped the progression of their disease. Only 14% of patients didn’t appear to see any benefit from the drug.

As dramatic as the responses to Zelboraf can be, they may not last. By seven months, half the patients in the study had stopped responding to the medication.

But even a temporary response appears to extend survival. Half the patients in the study were still alive after 16 months.

“There’s a feeling that patients respond for a very short time and then relapse. Obviously that’s true, there are patients like that. But there is a group of patients who respond for much longer periods of time, and a number of patients are still alive at a year or two years. And I think we didn’t appreciate those numbers before,” says researcher Jeffrey A. Sosman, MD, director of the melanoma and tumor immunotherapy program at the Vanderbilt-Ingram Cancer Center in Nashville, Tenn.

1 | 2 | 3

Today on WebMD

Malignant melanoma
About 40-50 percent of those who live to be 65 may get it. Here’s how to spot early.
Woman checking out tan lines
There’s a dark side to that strive for beauty. See them here.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Lung cancer xray
See it in pictures, plus read the facts.
12 Ways to Protect Your Skin from Melanoma
precancerous lesions slideshow
Do You Know Your Melanoma ABCs
15 Cancer Symptoms Men Ignore
screening tests for men
Vitamin D
Is That Mole Skin Cancer
Brilliant sun rays